Medindia LOGIN REGISTER
Medindia

Side effect(s) of Atezolizumab


Review the side-effects of Atezolizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  General:
Fatigue, fever and peripheral edema (accumulation of fluid which result in swelling).

  Gastrointestinal:
Nausea, vomiting, constipation, diarrhea, abdominal pain, decreased appetite.

  Musculoskeletal system:
Neck pain, back pain and joint pain.

  Respiratory system:
Difficulty in breathing and cough.

  Kidney and Urinary system:
Hematuria (blood in urine) and urinary tract infections.

  Skin:
Rash and severe itching of the skin.

  Immune-related side effects:
These side effects include inflammation of organs like lungs, liver, colon and hormone-secreting glands (endocrine organs).

Other Precautions :

• Patients must be advised to consult the doctor if there is any sign of myasthenia gravis (neuromuscular disease), meningoencephalitis (inflammation of brain and its surrounding membranes) and Gullian Barre syndrome (immune related nervous disorder) after taking atezolizumab.
• Do not breastfeed while taking atezolizumab and leave a gap of at least five months after the last dose before breastfeeding the baby.
• While diluting the infusion, atezolizumab should be mixed only by gentle inversion, do not shake.
• The empty and partially used vials should be discarded immediately. They must not be reused after opening.

Drug Name : Atezolizumab

Atezolizumab generic Atezolizumab is a programmed death ligand 1 (PD-L1) monoclonal antibody. It acts by activating the anti-tumor immune response and is prescribed for the treatment of advanced or metastatic urothelial carcinoma (a type of cancer which affects the urinary bladder and its related parts). Metastatic cancer refers to a cancer that has spread to distant parts of the body. Atezolizumab is approved for use in patients who have disease progression. • During or following chemotherapy which contains a platinum-based drug in the regimen. • With platinum-based chemotherapy administered either before or after surgery for the cancer.


Advertisement